NCT04175431View on ClinicalTrials.gov

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2020

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2031

Conditions
Prostate Adenocarcinoma
Interventions
PROCEDURE

Positron Emission Tomography

Undergo fluciclovine PET/CT

PROCEDURE

Lymphadenectomy

Undergo lymphadenectomy

RADIATION

Radiation Therapy

Undergo radiation therapy

DRUG

Abiraterone Acetate

Given PO

DRUG

Prednisone

Given PO

PROCEDURE

Computed Tomography

Undergo fluciclovine PET/CT

DRUG

Abiraterone

Given PO

PROCEDURE

PSMA PET Scan

Undergo PSMA PET scan

Trial Locations (2)

15232

RECRUITING

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Blue Earth Diagnostics
All Listed Sponsors
collaborator

Blue Earth Diagnostics

INDUSTRY

lead

University of Washington

OTHER